Podcasts about life sciences

Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At CDMO Live 2025, a panel sponsored by Aizon explored how pharma companies are transforming external manufacturing operations through digital integration, with experts from sharing practical approaches to implementation.The Digital Divide: Big Pharma vs Mid-Size PlayersThe panellists painted a stark contrast in digital maturity across the pharmaceutical manufacturing landscape. Dave O'Gara, pharmaceutical business consultant at Aizon with over 30 years experience at Novartis, outlined the current state of play."When you move into pharma and segregate into big pharma, they have digital strategies... When you move into the mid-range CDMOs and smaller CMOs, it's not so active," O'Gara explained, highlighting what he termed a "massive opportunity" for mid-size players.Franziskus Kath, founder of Kath-Consulting and former VP of Emerging Technology for QA at Johnson & Johnson, confirmed this assessment: "The larger the companies, the more digital is already there... Most of them have been for the past eight to 10 years really tackling the topic."From the CDMO perspective, Vishnu Dwadasi, Director of Life Sciences at West Monroe, described significant implementation challenges: "A lot of these companies are still very manual, so they have to move from paper to digital and then digital to eventually leveraging analytics and AI."Download the full report

SomX's Hue Penson, Andrew Hair and Hollie Ruda dive into the weeks' healthtech stories.00:00 - Intro 01:25 - Musk's Neuralink raises $650 million in latest funding as clinical trials begin + A Neuralink Rival Just Tested a Brain Implant in a Person12:10 - atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies20:13 - NHS England pauses ‘ground-breaking' AI project following GP data concerns

In a groundbreaking development for the digital health world, Eli Lilly, one of the world's largest pharmaceutical companies, has filed lawsuits against a growing number of telehealth companies over the sale of compounded drugs Mounjaro and Zepbound, two popular GLP-1 medications. Nawa Lodin, Associate, Wilson Sonsini Goodrich & Rosati, and Lauren Petrin, Associate, Wiley Rein, discuss the background of compounding and when it is allowed under FDA regulations; the legal and regulatory issues at play in Eli Lilly's lawsuits, including issues related to the corporate practice of medicine and FDA regulations; and key compliance considerations. Watch this episode: https://www.youtube.com/watch?v=XstaVQGtY24AHLA's Health Law Daily Podcast Is Here! AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Premium members. Get all your health law news from the major media outlets on this new podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

For decades, multinational corporations have used sophisticated strategies to shift profits away from where they do business. As a result, countries around the world lose an estimated US$500 billion annually in unpaid taxes, with developing nations hit particularly hard.In the first episode of The 15% solution, we explore how companies have exploited loopholes in the global tax system. We speak to Annette Alstadsæter, director of the Centre for Tax Research at the Norwegian University of Life Sciences, and Tarcisio Diniz Magalhaes, a professor of tax law at the University of Antwerp in Belgium. In 2021, after years of international negotiations, the Organisation for Economic Co-operation and Development unveiled a global tax deal designed to address tax avoidance through a minimum corporate tax rate of 15%. But will this new framework actually work? And what happens when major economies refuse to participate? The 15% solution explores why a new global tax regime is needed, whether it can fix a broken system, and what's at stake if it fails.This episode of The Conversation Weekly was written and produced by Mend Mariwany. Gemma Ware is the executive producer. Mixing and sound design by Eloise Stevens and theme music by Neeta Sarl. Sound design and mixing by Eloise Stevens and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation. Donation

Welcome to Automating Quality, the life sciences–focused show that bridges the gap between automation and quality management. In today's episode, Ed and Philippe explore how quality can bring added value to a company and discuss strategies to shift organizational mindsets to unlock the full potential of quality departments. Ed Siurek brings over 30 years of hands-on experience in applying quality standards and ensuring regulatory compliance in the pharmaceutical and medical device industries. He has trained hundreds of quality professionals and is a strong advocate for positioning quality as a driver of business value. After 13 years with a consulting firm, Ed recently transitioned full-time to his own company, ES3 Solutions Inc.   Key Takeaways 00:53 – Introducing Ed Siurek 02:20 – Why is quality sometimes perceived as a cost? 05:50 – Always remember: our products are ultimately used on people 09:02 – “If it's not written down, it didn't happen” 10:20 – Use your risk report — don't let it collect dust 13:20 – How are regulatory bodies viewed in the industry today? 21:15 – What is the role of a quality plan?   Contact us at solabs-podcast@solabs.com for questions or suggestions. Contact Ed Siurek at Always improving ES3 Solutions

In this episode of Tiny Show and Tell Us, we talk about what dark energy and dark matter are made out of and how knowing more could upend our understanding of the Big Bang. Then we cover microchimeric cells — cells transferred between baby and mom — and how new research in mice shows that fetal cells that took residency in mom from a first pregnancy are replaced by new fetal cells of a second pregnancy.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tune in as Glenn Hunzinger, PwC's Health Industries Leader, and Phil Scalfani, PwC's Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration's executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.  Discussion Highlights: The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countriesPharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroadA proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developmentsSpeakers:Glenn Hunzinger, Health Industries Leader, PwCPhilip Sclafani, Partner, Pharma & Life Sciences, PwCLinked materials:Most Favored Nation prescription drug pricing Executive OrderFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.What makes this conversation essential listening:96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubatorsThree critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraintsThe future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusionThis isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian GiehringConnect with Tom Valentin:LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091bWebsite: www.csem.ch/enEmail: thomas.valentin@csem.chNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

In science, the Blavatnik Award for Young Scientists of 2025 were announced this week. The prestigious award went to three early-career scientists among 36 nominees and also includes a 100,000 dollar grant for each one for their groundbreaking research in three fields – Life Sciences, Chemical Sciences and Physical Sciences & Engineering. We spoke with one of the recipients, Dr. Benjamin Palmer, Assistant Professor of Chemistry at Ben-Gurion University of the Negev. He is being recognized for his pioneering research on how organisms form crystals. (photo: courtesy) See omnystudio.com/listener for privacy information.

We welcome Karla Childers to AI Uncovered. Karla is a long-standing leader in bioethics and data transparency in the pharmaceutical industry. As part of the Office of the Chief Medical Officer at Johnson & Johnson, she brings deep expertise in navigating the ethical implications of emerging technologies, especially artificial intelligence, in medicine and drug development.In this episode, Tim and Karla explore the intersection of AI, bioethics and patient-centered development. They discuss how existing ethical frameworks are being challenged by the rise of generative AI and why maintaining human oversight is critical—especially in high-context areas like clinical trial design, consent and medical communications. Karla also shares her views on the future of data privacy, the complexity of patient agency and how to avoid losing trust in the race for efficiency.Karla is a strong advocate for using innovation responsibly. From her work with internal bioethics committees to her perspective on evolving regulatory expectations, she offers bold insights into how the industry can modernize without compromising ethics or equity.Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries. With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

What happens when cutting-edge science meets compassion? In this episode of Sounds of Science, host Mary Parker sits down with two pioneers reshaping the future of research: Elizabeth Nunamaker, Executive Director of Global Animal Welfare and Training at Charles River, and Dr. Megan LaFollette, Executive Director of the 3Rs Collaborative. From digital biomarkers to environmental health monitoring, they reveal how innovation and collaboration are redefining what's possible in animal welfare — and raising the bar for ethical, high-quality research. Tune in to explore the tools, strategies, and bold ideas driving meaningful change across the scientific community.Show NotesAdvancing Alternatives | Charles RiverEvolving Animal Welfare: Science, Ethics, and Innovation | Sounds of Science Can You Practice High-quality Science and 3Rs? | Eureka BlogAnimals in Research | Charles RiverResearch Models & Services | Charles River

We love to hear from our listeners. Send us a message. On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders. Rao also talks about atai's hub and spoke model for investing in other psychedelic companies, what MAPS/Lykos Therapeutics got wrong in the run-up to FDA's review of Lykos's MDMA candidate for PTSD, and whether psychedelic therapies need the "trip" to catalyze network disruption and neuroplasticity in the brain. This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Managing editor Anna Townshend spoke with two team members at BioMADE, which is one of nine different Manufacturing Innovation Institutes started by the Department of Defense. This particular group is focused on building the U.S. bioindustrial economy. There are many companies and scientists doing great work using chemical waste products to create new products that we often lack a domestic supply chain for, and the organization is also focused on commercializing and scaling the technology needed to do this work and the workforce to support the industry. Jill Zullo, executive vice president and chief operating officer at BioMADE, has a long career supporting sustainable products and focused on new bioindustrial markets. Most recently, she worked at Cargill, as interim president & CEO of NatureWorks, a Cargill joint venture focused on biomanufacturing development to replace fossil fuel-based materials. Tim Dobbs, data architect for BioMADE's data science team, is a chemical engineer with a degree from the University of Connectivity and a master's degree in Life Sciences. At BioMADE, he designs, models and deploys data models to BioMADE's member organizations. He and the technology team at BioMADE provide the unified computational infrastructure for bioproduction-centered collaboration across industry, academia and government.

This podcast was recorded in front of a live audience in March of 2025. The panel discusses unique career paths in the life sciences, with a particular emphasis on roles in academic administration and features Eric Loo,'07 BSc,'13 PhD; Grant Kemp, '07 BSc,'13 PhD and Helen Coe,'04 BSc,'10 PhD

Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us a textIn this episode of the Life Science Success Podcast my guest is Elizabeth Chabe, the founder of High Touch Group (HTG) and an expert in science marketing with a distinguished background spanning research universities, national labs, and technology transfer offices. Elizabeth brings a wealth of experience in guiding researchers through technology commercialization and providing data-driven marketing strategies for life sciences and diagnostics companies, and is also the author of "The Giant's Ladder: The Science Professional's Blueprint for Marketing Success."00:00 Introduction to Life Science Success Podcast00:29 Meet Elizabeth Chabe: Entrepreneurial Journey01:12 Early Business Ventures and Education03:59 Transition to Life Sciences and Marketing06:41 Challenges and Insights from Academia11:39 Founding High Touch Group14:55 High Touch Group Services and Success Metrics19:34 The Giants Ladder: A Book for Founders23:10 Commercializing Innovations: Strategies and Pitfalls23:56 Challenges in Creating Market Demand25:26 Common Pitfalls in Product Development25:56 Importance of Audience Research27:05 Y Combinator's Critique on Entrepreneurial Approaches27:47 The Role of Multi-Skilled Teams in Marketing29:55 Successful Marketing Campaigns34:32 Innovative Trends in Life Sciences Marketing38:00 Leadership Advice and Team Collaboration42:54 Concerns About Federal Funding Cuts46:33 Excitement for Future Diagnostic Products

In this special episode of Trending Health, Mindy McGrath and Karen Baldry explore how recent changes across the U.S. federal health agencies and policies from the new administration are impacting the life sciences and biotech industry compounding with other pressures like the IRA, tariffs, and budget constraints. From launch delays at the FDA to supply chain strain and evolving patient access challenges, Mindy and Karen provide strategic considerations for commercial leaders as they navigate these shifts and uncertainties.   To learn more about how we can help your team with scenario planning and navigating these strategic decisions, reach out to . Check out our recent insights for more information: U.S. Federal Health Agency Layoffs Pose Strategic Risk and Disruption to Life Sciences & The Case for Strategic Transformation: An Executive Conversation with Vynamic's Leaders    Podcast Tags: healthcare, life sciences, public health, life sciences trends, healthcare strategy, health innovation    Panel – Mindy McGrath, Karen Baldry  Research & Production – Mindy McGrath, Karen Baldry, Everly Petruzzelli  Recording & Editing – Mike Liberto, Rachel Skonecki   

Efficiency is a top benefit of AI, but how do you create value beyond that? Aditya Kudumala, Deloitte's Global Life Sciences & Health care AI lead, explains how the “string of pearls” methodology turns AI into a strategic lever for broader transformation.

This is the daily Tech and Business Report. Today, KCBS Radio anchor Eric Thomas spoke with Bloomberg's Robert Langreth. The cost of cancer drugs has been skyrocketing, but now questions are being raised about just how beneficial they are. A recent analysis in JAMA Oncology found that a drop in cancer deaths between 1975 and 2020 was due mostly to improved screening and preventative health measure, and not new treatments.

Today's guest is Daniel Ferrante, AI Leader in R&D and Data Strategy at Deloitte. Daniel joins Emerj CEO and Head of Research Daniel Faggella on today's show to delve into the intersection of AI, data strategy, and research and development across industries such as agriculture, life sciences, and materials science. Ferrante breaks down the core challenges organizations face in harnessing data to unlock AI's potential and drive efficiencies in R&D processes. Ferrante also emphasizes the importance of contextualizing data through a multimodal framework — Deloitte's Atlas — to bridge gaps between disparate datasets and ontologies. He outlines how AI models, including large language models (LLMs), can be leveraged to label and map complex data landscapes. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Why Most Healthcare Brands Fail (And How to Fix It)In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling.You'll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also shares lessons from working with emerging startups and large enterprises, offering a strategy for aligning commercial goals with patient and provider trust.

In this episode of The Poultry Nutrition Blackbelt Podcast, Dr. Sara Llamas-Moya from Kerry shares how enzyme innovation transforms poultry nutrition. She explains end-to-end enzyme development, sustainability through proteases, and how enzyme specificity affects feed formulation. Listen now on all major platforms!"Proteases support better products, better processes, and better planet outcomes for poultry producers globally."Meet the guest: Dr. Sara Llamas-Moya holds a Ph.D. in Life Sciences from the University of Limerick and a Master's in Food, Nutrition, and Health from University College Dublin. Currently serving as Global Scientific Affairs & Applications - Animal Performance Solutions at Kerry, she brings nearly two decades of experience in enzyme development and monogastric nutrition. Her work supports sustainable, performance-driven solutions in poultry nutrition.Liked this one? Don't stop now — Here's what we think you'll love!Dr. Kyle Smith: Organic Enzymes in Poultry Feed | Ep. 43Dr. Ryan Arsenault: Gut Health in Poultry | Ep. 46Dr. Wilmer Pacheco: Multi-Carbohydrase Enzyme for Poultry | Ep. 82What you'll learn:(00:00) Highlight(01:32) Introduction(03:14) Enzyme innovation(05:02) Sustainability focus(09:07) Protein utilization(11:32) Protease technology(13:49) Enzyme benefits(17:17) Closing thoughtsThe Poultry Nutrition Blackbelt Podcast is trusted and supported by innovative companies like:* Kerry* Kemin- Zinpro- Anitox- BASF- Barentz- Poultry Science Association

Beim Schweizer Verband für Life Sciences freut man sich über die Nachricht, dass das globale Onkolgie-Unternehmen "BeOne" seinen Firmensitz nach Basel verlegt. Dies zeige die Attraktivität des Pharma-Standorts Basel. Ausserdem: · Schweizerische Rheinhäfen kaufen Schifffahrts-Simulator · Basler Regierung rechnet weiterhin mit leichtem Minus fürs 2025

EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Organizations must recognize that AI risk management is a shared responsibility across the entire organization, not solely confined to cybersecurity, legal, or compliance teams.  In this episode, Michael Crowthers, Managing Director of Life Sciences Digital Quality & Compliance, and Chris Knackstedt, Managing Director of Cyber and Strategic Risk Practice at Deloitte & Touche, discuss the major challenges to AI adoption, highlighting governance, ethics, and compliance as top concerns. They emphasize the importance of integrating AI governance into existing risk management frameworks and navigating regulatory uncertainty, talent gaps, and ethical usage policies. The conversation also explores risks posed by AI agents, such as runaway behavior, misaligned learning, and context untraceability, stressing the need for human oversight and robust behavioral evaluations. Looking ahead, Michael anticipates a rise in governance tech to manage evolving AI risks, while Chris encourages organizations to build on their cybersecurity foundation and maintain momentum in AI strategy. Tune in and learn how to navigate the complex landscape of AI risk management and secure adoption! Resources:  Connect and follow Mike Crowthers on LinkedIn. Connect and follow Chris Knackstedt on LinkedIn. Learn more about Deloitte on their LinkedIn and website. Subscribe to The Current, Deloitte Cyber's quick-read series. Read our life sciences and health care industry insights. Visit the Deloitte AI Institute™ website. Explore The State of Generative AI in the enterprise 2024 year-end report. 

Host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests.This week his guests are Joe Morrow, IT Director, Technology Services at OSF Healthcare, and Sandra Colner, Global GM/Sr. Director of Healthcare and Life Sciences at Dell Technologies. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Audio FileGround Truths can also be found on Apple Podcasts, Spotify and YouTube.The UK is the world leader in human genomics, and laid the foundation for advancing medicine with the UK Biobank, Genomes England and now Our Future Health (w/ 5 million participants). Sir John Bell is a major force in driving and advising these and many other initiatives. After 22 years as the Regius Professor of Medicine at the University of Oxford he left in 2024 to be President of the Ellison Institute of Technology. Professor Bell has been duly recognized in the UK: knighted in 2015 and appointed Companion of Honor in 2023. In our conversation, you will get a sense for how EIT will be transformational for using A.I. and life science for promoting human health.Transcript with audio links Eric Topol (00:06):Hello, this is Eric Topol from Ground Truths. And I'm really delighted to welcome today, Sir John Bell who had an extraordinary career as a geneticist, immunologist, we'll talk about several initiatives he's been involved with during his long tenure at University of Oxford, recently became head of the Ellison Institute of Technology (EIT) in the UK. So welcome, John.Sir John Bell (00:30):Thanks, Eric. Thanks very much for having me.Eric Topol (00:34):Well, I think it's just extraordinary the contributions that you have made and continue to make to advance medicine, and I thought what we could do is get into that. I mean, what's interesting, you have had some notable migrations over your career, I think starting in Canada, at Stanford, then over as Rhodes Scholar in Oxford. And then you of course had a couple of decades in a very prestigious position, which as I understand was started in 1546 by King Henry VII, and served as the Regius Professor of Medicine at the University of Oxford. Do I have that right?Sir John Bell (01:11):It was actually Henry VIII, but you were close.Eric Topol (01:14):Henry VIII, that's great. Yeah. Okay, good. Well, that's a pretty notable professorship. And then of course in recent times you left to head up this pretty formidable new institute, which is something that's a big trend going on around the world, particularly in the US and we'll talk about. So maybe we can start with the new thing. Tell us more about the Ellison Institute of Technology (EIT), if you will.Sir John Bell (01:47):Yeah. So as you know, Larry Ellison has been one of the great tech entrepreneurs focused really on developing terrific databases over his career and through Oracle, which is the company that he founded. And Larry is really keen to try and give back something substantial to the world, which is based on science and technology. So he and I did quite a bit together over the Covid pandemic. He and I talked a lot about what we're doing and so on. He came to visit afterwards and he had, I think he decided that the right way to make his contributions would be to set up an institute that would be using the state-of-the-art science and technology with a lot of AI and machine learning, but also some of the other modern tools to address the major problems in healthcare, in food security, in green energy and climate change and in global governance.Sir John Bell (02:49):So anyway, he launched this about 18 months ago. He approached me to ask whether I would run it. He wanted to set it up outside Oxford, and he wanted to do something which is a bit different than others. And that is his view was that we needed to try and create solutions to these problems which are commercially viable and not all the solutions are going to be commercially viable, but where you can create those, you make them sustainable. So the idea is to make sure that we create solutions that people want to buy, and then if they buy them, you can create a sustainable solution to those issues. So we are actually a company, but we are addressing many of the same problems that the big foundations are addressing. And the big issues that you and I talk about in health, for example, are all on our list. So we're kind of optimistic as to where this will go and Larry's supporting the project and we're going to build out an institute here which will have about 5,000 people in it, and we'll be, I think a pretty exciting new addition to the science and technology ecosystem globally.Eric Topol (04:02):Well, I know the reverberations and the excitement is palpable and some of the colleagues I've spoken to, not just in England, but of course all over the world. So congratulations on that. It was a big move for you to leave the hardcore academics. And the other thing I wanted to ask you, John, is you had distinguished your career in immunology, in genetics, type 1 diabetes and other conditions, autoimmune conditions, and now you've really diversified, as you described with these different areas of emphasis at the new institute. Is that more fun to do it or do you have deputies that you can assign to things like climate change in other areas?Sir John Bell (04:50):Trust me, Eric, I'm not making any definitive decisions about areas I know nothing about, but part of this is about how do you set up leadership, run a team, get the right people in. And I have to say one of the really interesting things about the institute is we've been able to recruit some outstanding people across all those domains. And as you know, success is almost all dependent on people. So we're really pretty optimistic we're going to have a significant impact. And of course, we also want to take risks because not a lot of point in us doing stuff that everybody else is doing. So we're going to be doing some things that are pretty way out there and some of them will fail, so we are just going to get used to trying to make sure we get a few of them across the finish line. But the other thing is that, and you've experienced this too, you never get too old to learn. I mean, I'm sucking up stuff that I never thought I would ever learn about, which is fun actually, and really marvel.Eric Topol (05:55):It's fantastic. I mean, you've really broadened and it's great that you have the runway to get these people on board and I think you're having a big building that's under construction?Sir John Bell (06:07):Yeah, we've got the original building that Larry committed to is about 330,000 square feet of space. I mean, this is completely amazing, but we are of course to accommodate up to 5,000 people, we're going to need more than that. So we are looking at a much wider campus here that'll involve more than just that building. I think we'll end up with several million square feet of space by the time we're finished. So mean, it's a really big project, but we've already made progress in some domains to try and get projects and the beginnings of companies on the road to try and solve some of the big problems. So we're quite excited about it.Eric Topol (06:49):Now you, I assume it's pretty close to Oxford, and will you have some kind of inter interactions that are substantial?Sir John Bell (06:58):Yeah, so the university's been terrific about this actually, because of course most universities would say, well, why don't you do it inside the university and just give us the money and it'll all be fine. So of course Larry. Larry wasn't born yesterday, so I said, well, thank you very much, but I think we'll probably do this nearby. But the university also realized this is a really exciting opportunity for them and we've got a really good relationship with them. We've signed an agreement with them as to who will work where. We've agreed not to steal a lot of their staff. We're going to be bringing new people into the ecosystem. Some of the university people will spend some time with us and sometime in the university, so that will help. But we're also bringing quite a few new people into the setting. So the university has been really positive. And I think one of the things that's attractive to the university, and you'll be familiar with this problem in the UK, is that we're quite good. The discovery science here is pretty good.Sir John Bell (08:06):And we do startups now at scale. So Oxford does lots of little startup companies in the biotech space and all the rest of it, but we never scale any of these companies because there isn't the depth of capital for scaling capital to get these things scaled. And so, in a way what we're trying to do here at Ellison actually avoids that problem because Larry knows how to scale companies, and we've got the financial support now. If we have things that are really successful, we can build the full stack solution to some of these problems. So I think the university is really intrigued as to how we might do that. We're going to have to bring some people in that know how to do that and build billion dollar companies, but it's sufficiently attractive. We've already started to recruit some really outstanding people. So as a way to change the UK system broadly, it's actually quite a good disruptive influence on the way the thing works to try and fix some of the fundamental problems.Eric Topol (09:07):I love that model and the ability that you can go from small startups to really transformative companies have any impact. It fits in well with the overall objectives, I can see that. The thing that also is intriguing regarding this whole effort is that in parallel we've learned your influence. The UK is a genomics world leader without any question and no coincidence that that's been your area of emphasis in your career. So we've watched these three initiatives that I think you were involved in the UK Biobank, which has had more impact than any cohort ever assembled. Every day there's another paper using that data that's coming out. There's Genomes England, and then now Our Future Health, which a lot of people don't know about here, which is well into the 5 million people enrollment. Can you tell us about, this is now 15 years ago plus when these were started, and of course now with a new one that's the biggest ever. What was your thinking and involvement and how you built the UK to be a world leader in this space?Sir John Bell (10:26):So if you turn the clock back 20 years, or actually slightly more than 25 years ago, it was clear that genomics was going to have a play. And I think many of us believed that there was going to be a genetic element to most of the major common disease turn out to be true. But at the time, there were a few skeptics, but it seemed to us that there was going to be a genetic story that underpinned an awful lot of human disease and medicine. And we were fortunate because in Oxford as you know, one of my predecessors in the Regius job was Richard Doll, and he built up this fantastic epidemiology capability in Oxford around Richard Peto, Rory Collins, and those folks, and they really knew how to do large scale epidemiology. And one of the things that they'd observed, which is it turns out to be true with genetics as well, is a lot of the effects are relatively small, but they're still quite significant. So you do need large scale cohorts to understand what you're doing. And it was really Richard that pioneered the whole thinking behind that. So when we had another element in the formula, which was the ability to detect genetic variation and put that into the formula, it seemed to me that we could move into an era where you could set up, again, large cohorts, but build into the ability to have DNA, interrogate the DNA, and also ultimately interrogate things like proteomics and metabolomics, which were just in their infancy at that stage.Sir John Bell (12:04):Very early on I got together because I was at that stage at the Nuffield Chair of Medicine, and I got together, Rory and Richard and a couple of others, and we talked a little bit about what it would look like, and we agreed that a half a million people late to middle age, 45 and above would probably over time when you did the power calculations, give you a pretty good insight in most of the major diseases. And then it was really a question of collecting them and storing the samples. So in order to get it funded at the time I was on the council of the MRC and George Radda, who you may remember, was quite a distinguished NMR physiologist here. He was the chief executive of the MRC. So I approached him and I said, look, George, this would be a great thing for us to do in the UK because we have all the clinical records of these people going back for a decade, and will continue to do that.Sir John Bell (13:01):Of course, we immediately sent it out to a peer review committee in the MRC who completely trashed the idea and said, you got to be joking. So I thought, okay, that's how that lasted. And I did say to George, I said, that must mean this is a really good idea because if it had gone straight through peer review, you would've known you were toast. So anyway, I think we had one more swing at peer review and decided in the end that wasn't going to work. In the end, George to his credit, took it to MRC council and we pitched it and everybody thought, what a great idea, let's just get on and do it. And then the Wellcome came in. Mark Walport was at the Wellcome at the time, great guy, and did a really good job at bringing the Wellcome on board.Sir John Bell (13:45):And people forget the quantum of money we had to do this at the time was about 60 million pounds. I mean, it wasn't astonishly small. And then of course we had a couple of wise people who came in to give us advice, and the first thing they said, well, if you ever thought you were really going to be able to do genetics on 500,000 people, forget it. That'll never work. So I thought, okay, I'll just mark that one out. And then they said, and by the way, you shouldn't assume you can get any data from the health service because you'll never be able to collect clinical data on any of these people. So I said, yeah, yeah, okay, I get it. Just give us the money and let us get on. So anyway, it's quite an interesting story. It does show how conservative the community actually is for new ideas.Sir John Bell (14:39):Then I chaired the first science committee, and we decided about a year into it that we really needed the chief executive. So we got Rory Collins to lead it and done it. I sat on the board then for the next 10 years, but well look, it was a great success. And as you say, it is kind of the paradigm for now, large genetic epidemiology cohorts. So then, as you know, I advise government for many years, and David Cameron had just been elected as Prime Minister. This was in about 2010. And at the time I'd been tracking because we had quite a strong genomics program in the Wellcome Trust center, which I'd set up in the university, and we were really interested in the genetics of common disease. It became clear that the price of sequencing and Illumina was now the clear leader in the sequencing space.Sir John Bell (15:39):But it was also clear that Illumina was making significant advances in the price of sequencing because as you remember, the days when it cost $5,000 to do a genome. Anyway, it became clear that they actually had technology that gets you down to a much more sensible price, something like $500 a genome. So I approached David and I said, we are now pretty sure that for many of the rare diseases that you see in clinical practice, there is a genetic answer that can be detected if you sequenced a whole genome. So why don't we set something up in the NHS to provide what was essentially the beginnings of a clinical service to help the parents of kids with various disabilities work out what's going on, what's wrong with their children. And David had had a child with Ohtahara syndrome, which as you know is again, and so David was very, he said, oh God, I'll tell you the story about how awful it was for me and for my wife Samantha.Sir John Bell (16:41):And nobody could tell us anything about what was going on, and we weren't looking for a cure, but it would've really helped if somebody said, we know what it is, we know what the cause is, we'll chip away and maybe there will be something we can do, but at least you know the answer. So anyway, he gave us very strong support and said to the NHS, can you please get on and do it? Again massive resistance, Eric as you can imagine, all the clinical geneticists said, oh my God, what are they doing? It's complete disaster, dah, dah, dah. So anyway, we put on our tin hats and went out and got the thing going. And again, they did a really good job. They got to, their idea was to get a hundred thousand genomes done in a reasonable timeframe. I think five years we set ourselves and the technology advance, people often underestimate the parallel development of technology, which is always going on. And so, that really enabled us to get that done, and it still continues. They're doing a big neonatal program at the moment, which is really exciting. And then I was asked by Theresa May to build a life science strategy because the UK, we do this stuff not as big and broad as America, but for a small country we do life sciences pretty well.Eric Topol (18:02):That's an understatement, by the way. A big understatement.Sir John Bell (18:04):Anyway, so I wrote the strategies in 2017 for Theresa about what we would do as a nation to support life sciences. And it was interesting because I brought a group of pharma companies together to say, look, this is for you guys, so tell us what you want done. We had a series of meetings and what became clear is that they were really interested in where healthcare was going to end up in the next 20 years. And they said, you guys should try and get ahead of that wave. And so, we agreed that one of the domains that really hadn't been explored properly, it was the whole concept of prevention.Sir John Bell (18:45):Early diagnosis and prevention, which they were smart enough to realize that the kind of current paradigm of treating everybody in the last six months of life, you can make money doing that, there's no doubt, but it doesn't really fix the problem. And so, they said, look, we would love it if you created a cohort from the age of 18 that was big enough that we could actually track the trajectories of people with these diseases, identify them at a presymptomatic stage, intervene with preventative therapies, diagnose diseases earlier, and see if we could fundamentally change the whole approach to public health. So we anyway, went back and did the numbers because of course at much wider age group, a lot of people don't get at all sick, but we thought if we collected 5 million people, we would probably have enough. That's 10% of the UK adult population.Sir John Bell (19:37):So anyway, amazingly the government said, off you go. We then had Covid, which as you know, kept you and I busy for a few years before we could get back to it. But then we got at it, and we hired a great guy who had done a bit of this in the UAE, and he came across and we set up a population health recruitment structure, which was community-based. And we rapidly started to recruit people. So we've now got 2.9 million people registered, 2.3 million people consented, and we've got blood in the bank and all the necessary data including questionnaire data for 1.5 million people growing up. So we will get to 5 million and it's amazing.Eric Topol (20:29):It is. It really is, and I'm just blown away by the progress you've made. And what was interesting too, besides you all weren't complacent about, oh, we got this UK Biobank and you just kept forging ahead. And by the way, I really share this importance of finally what has been a fantasy of primary prevention, which never really achieved. It's always, oh, after a heart attack. But that's what I wrote about in the Super Agers book, and I'll get you a copy.Sir John Bell (21:02):No, I know you're a passionate believer in this and we need to do a lot of things. So we need to work out what's the trial protocol for primary prevention. We need to get the regulators on board. We've got to get them to understand that we need diagnostics that define risk, not disease, because that's going to be a key bit of what we're going to try and do. And we need to understand that for a lot of these diseases, you have to intervene quite early to flatten that morbidity curve.Eric Topol (21:32):Yeah, absolutely. What we've learned, for example, from the UK Biobank is not just, of course the genomics that you touched on, but the proteomics, the organ clocks and all these other layers of data. So that gets me to my next topic, which I know you're all over it, which is AI.Eric Topol (21:51):So when I did the NHS review back in 2018, 2019, the group of people which were amazing that I had to work with no doubt why the UK punches well beyond its weight. I had about 50 people, and they just said, you know what? Yeah, we are the world leaders in genomics. We want to be the world leader in AI. Now these days you only hear about US and China, which is ridiculous. And you have perhaps one of the, I would say most formidable groups there with Demis and Google DeepMind, it's just extraordinary. So all the things that the main foci of the Ellison Institute intersect with AI.Sir John Bell (22:36):They do. And we, we've got two underpinning platforms, well actually three underpinning platforms that go across all those domains. Larry was really keen that we became a real leader in AI. So he's funded that with a massive compute capacity. And remember, most universities these days have a hard time competing on compute because it's expensive.Eric Topol (22:57):Oh yeah.Sir John Bell (22:58):So that is a real advantage to us. He's also funded a great team. We've recruited some people from Demis's shop who are obviously outstanding, but also others from around Europe. So we really, we've recruited now about 15 really outstanding machine learning and AI people. And of course, we're now thinking about the other asset that the UK has got, and particularly in the healthcare space is data. So we do have some really unique data sets because those are the three bits of this that you need if you're going to make this work. So we're pretty excited about that as an underpinning bit of the whole Ellison Institute strategy is to fundamentally underpin it with very strong AI. Then the second platform is generative biology or synthetic biology, because this is a field which is sort of, I hesitate to say limped along, but it's lacked a real focus.Sir John Bell (23:59):But we've been able to recruit Jason Chin from the LMB in Cambridge, and he is one of the real dramatic innovators in that space. And we see there's a real opportunity now to synthesize large bits of DNA, introduce them into cells, microbes, use it for a whole variety of different purposes, try and transform plants at a level that people haven't done before. So with AI and synthetic biology, we think we can feed all the main domains above us, and that's another exciting concept to what we're trying to do. But your report on AI was a bit of a turning point for the UK because you did point out to us that we did have a massive opportunity if we got our skates, and we do have talent, but you can't just do it with talent these days, you need compute, and you need data. So we're trying to assemble those things. So we think we'll be a big addition to that globally, hopefully.Eric Topol (25:00):Yeah. Well that's another reason why I am so excited to talk to you and know more about this Ellison Institute just because it's unique. I mean, there are other institutes as like Chan Zuckerberg, the Arc Institute. This is kind of a worldwide trend that we're seeing where great philanthropy investments are being seen outside of government, but none have the computing resources that are being made available nor the ability to recruit the AI scientists that'll help drive this forward. Now, the last topic I want to get into with you today is one that is where you're really grounded in, and that's the immune response.Eric Topol (25:43):So it's pretty darn clear now that, well, in medicine we have nothing. We have the white cell neutrophil to lymphocyte ratio, what a joke. And then on the other hand, we can do T and B cell sequencing repertoires, and we can do all this stuff, autoantibody screens, and the list goes on and on. How are we ever going to make a big dent in health where we know the immune system is such a vital part of this without the ability to check one's immune status at any point in time in a comprehensive way? What are your thoughts about that?Sir John Bell (26:21):Yeah, so you seem to be reading my mind there. We need to recruit you over here because I mean, this is exactly, this is one of our big projects that we've got that we're leaning into, and that is that, and we all experienced in Covid the ins and outs of vaccines, what works, what doesn't work. But what very clear is that we don't really know anything about vaccines. We basically, you put something together and you hope the trial works, you've got no intermediate steps. So we're building a really substantial immunophenotyping capability that will start to interrogate the different arms of the immune response at a molecular level so that we can use a combination of human challenge models. So we've got a big human challenge model facility here, use human challenge models with pathogens and with associated vaccines to try and interrogate which bits of the immune response are responsible for protection or therapy of particular immunologically mediated diseases or infectious diseases.Sir John Bell (27:30):And a crucial bit to that. And one of the reasons people have tried this before, but first of all, the depth at which you can interrogate the immune system has changed a lot recently, you can get a lot more data. But secondly, this is again, where the AI becomes important because it isn't going to be a simple, oh, it's the T-cell, it's going to be, well, it's a bit of the T cells, but it's also a bit of the innate immune response and don't forget mate cells and don't forget a bit of this and that. So we think that if we can assemble the right data set from these structured environments, we can start to predict and anticipate which type of immune response you need to stimulate both for therapy and for protection against disease. And hopefully that will actually create a whole scientific foundation for vaccine development, but also other kinds of immune therapy and things like cancer and potentially autoimmune disease as well. So that's a big push for us. We're just busy. The lab isn't set up. We've got somebody to run the lab now. We've got the human challenge model set up with Andy Pollard and colleagues. So we're building that out. And within six months, I think we'll be starting to collect data. So I'm just kind of hoping we can get the immune system in a bit more structured, because you're absolutely right. It's a bit pin the tail on the donkey at the moment. You have no idea what's actually causing what.Eric Topol (29:02):Yeah. Well, I didn't know about your efforts there, and I applaud that because it seems to me the big miss, the hole and the whole story about how we're going to advanced human health and with the recent breakthroughs in lupus and these various autoimmune diseases by just targeting CD19 B cells and resetting like a Ctrl-Alt-Delete of their immune system.Sir John Bell (29:27):No, it's amazing. And you wouldn't have predicted a lot of this stuff. I think that means that we haven't really got under the skin of the mechanistic events here, and we need to do more to try and get there, but there's steady advance in this field. So I'm pretty optimistic we'll make some headway in this space over the course of the next few years. So we're really excited about that. It's an important piece of the puzzle.Eric Topol (29:53):Yeah. Well, I am really impressed that you got all the bases covered here, and what a really exhilarating chance to kind of peek at what you're doing there. And we're going to be following it. I know I'm going to be following it very closely because I know all the other things that you've been involved with in your colleagues, big impact stuff. You don't take the little swings here. The last thing, maybe to get your comment, we're in a state of profound disruption here where science is getting gutted by a madman and his henchmen, whatever you want to call it, which is really obviously a very serious state. I'm hoping this is a short term hit, but worried that this will have a long, perhaps profound. Any words of encouragement that we're going to get through this from the other side of the pond?Sir John Bell (30:52):Well, I think regardless of the tariffs, the scientific community are a global community. And I think we need to remember that because our mission is a global mission, and we need to lean into that together. First of all, America is such a powerhouse of everything that's been done scientifically in the human health domain. But not only that, but across all the other domains that we work in, we can't really make the kind of progress that we need to without America being part of the agenda. So first of all, a lot of sympathy for you and your colleagues. I know it must be massively destabilizing for you, not be confident that the things that work are there to help you. But I'm pretty confident that this will settle down. Most of the science is for, well, all the science is really for public good, and I think the public recognizes it and they'll notice if it's not being prosecuted in the way that it has to be. And the global science community cannot survive without you. So we're all leaning in behind you, and I hope it will settle. One of my worries is that these things take years to set up and literally hours or minutes to destroy. So we can't afford to take years to set them back up again. So we do need to be a bit careful about that, but I still have huge confidence in what you guys can achieve and we're all behind you.Eric Topol (32:37):Well, that's really helpful getting some words of wisdom from you there, John. So this has been terrific. Thanks so much for joining, getting your perspective on what you're doing, what's important is so essential. And we'll stay tuned for sure.Sir John Bell (32:59):And come and visit us at the EIT, Eric. We'd be glad to see you.*******************************Some of the topics that John and I discussed—immunology, A.I., genomics, and prevention—are emphasized in my new book SUPER AGERS. A quick update: It will have a new cover after making the New York Times Bestseller list and is currently ranked #25 for all books on Amazon. Thanks to so many of you for supporting the book!Here are a few recent podcasts:Dax Shepard: Dr. Mike Sanjay Gupta ***********************Thanks for reading and subscribing to Ground Truths.If you found this interesting please share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths— newsletters, analyses, and podcasts—is free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

Host Gil Bashe welcomes Dan Sheeran, Amazon Web Services' General Manager for Healthcare and Life Sciences – in a far-reaching conversation about technology's impact on health. The discussion explores how cloud computing, data analytics, and artificial intelligence (AI) are accelerating innovation from drug discovery to patient care. Dan Sheeran shares insights from his front-line experience as a digital health entrepreneur and AWS leader, emphasizing a mission-driven approach to improving global health outcomes. Key themes include speeding up the development of new therapies, expanding telehealth access, strengthening healthcare security, and applying Amazon's customer-centric ethos to healthcare. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with Jenni Nordborg, Director of International Affairs at The Swedish Association of the Pharmaceutical Industry (LIF), to explore how national and European policies intersect to shape life sciences innovation. They discuss Sweden’s holistic governance model, the strategic framing of healthcare spending as an investment, and the challenges of aligning regional autonomy with EU‑wide regulatory frameworks. Key Topics:- National Strategy Spotlight: Sweden’s comprehensive life sciences strategy underscores government priorities and creates cross‑ministerial governance for innovation. - Regional Autonomy Dynamics: Balancing national directives with regional healthcare mandates enables tailored implementation and closer patient engagement. - Funding as Investment: Reframing healthcare budgets as long‑term investments is illustrated by Sweden’s hepatitis C program and emerging prevention initiatives. - Governance and Collaboration: The Office for Life Sciences and public‑private partnerships align industry, academia, and policymakers for cohesive action. - EU Policy Intersection: Navigating Europe’s complex regulatory landscape - from data protection periods to strategic autonomy - reveals opportunities to accelerate R&D and access. This episode uncovers the strategic mechanisms behind Sweden’s success in life sciences and offers a roadmap for harmonizing national and EU policies to boost innovation and patient access. It’s essential listening for policymakers, industry leaders, and healthcare stakeholders seeking practical guidance on aligning governance, funding, and regulation for sustainable pharmaceutical advancements.See omnystudio.com/listener for privacy information.

What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In our latest Life Science Solutions podcast, we sit down with Lydia Thomas from UNCW's Center for Innovation and Entrepreneurship to talk about the real-world gaps academic startups face—and how her team is helping solve them.From lacking investor networks to navigating IP challenges, Lydia shares how CIE supports faculty and students developing high-potential innovations. We also dive into the Blue Economy Index, plastic waste reduction in drug delivery, and how startups can partner with established life science companies to scale breakthrough technologies.Whether you're in pharma, biotech, or innovation strategy, this episode explores why the next big thing might just be sitting in a university lab—and what it'll take to bring it to market.

Matters Microbial #91: You Are What Your Genes Feed Your Microbiome May 16, 2025 Today, Dr. Emily Davenport, Assistant Professor in the Department of Biology and Huck Institutes of the Life Sciences at Penn State University, joins the #QualityQuorum to tell us about the research her team does, studying how our own genes impact our microbiomes.   Host: Mark O. Martin Guest: Emily Davenport Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A description of GWAS (“Genome Wide Association Study”).  Here is an introductory video about the concept. An explainer on organoids. An essay about the diversity of the host microbiome (i.e. is there a “healthy” microbiome?). An article of the work of Dr. Sarkis Mazamian on how individual host genes and bacterial genes can impact the microbiome. A nice write up for Dr. Mazamian's work showing how host genes and bacterial genes can work together…or not. An oldish video of how the infant microbiome develops over time by Dr. Rob Knight's research group. An article on the same topic from Dr. Ruth Ley. An essay on the mucosal microbiota, rather than the fecal microbiome. An interesting member of the human microbiome, Akkermansia that might be related to obesity. Another interesting member of the human microbiome, Bifidobacterium, which appears to be associated with host lactose metabolism.  Yes, there is a Giant Microbes plush toy. An overview of the impact of host genetics on the microbiome by Dr. Davenport.  A definition of heritability. An overview of the Hutterites and how their study has advanced genetics. An explainer of the power of twin studies in genetics. A fascinating article about ancient dental plaque microbiome by Dr. Davenport and others. Dr. Davenport's faculty website. Dr. Davenport's research group website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

In this episode of Flow Stars, we're joined by Anis Larbi, Medical & Scientific Affairs, Beckman Coulter Life Sciences. Anis chats about his experience working at the prestigious A*STAR in Singapore, where he led a dual career as both a principal investigator and the head of a core flow cytometry facility.He also shares his advocacy of networking, explains this inspired him to make the leap from academia to industry and discusses some of the snobbery some academics have about this transition.Watch or listen to all episodes of Flow Stars: flowstars.bitesizebio.com

In this episode of Investor Connect, we welcome Alan Foreman, the CEO of Be Secure, who discusses the transformative journey of his company in the realm of heart health. Alan shares that he founded Be Secure nine years ago after a lengthy career in Accenture's Life Sciences division. Currently, the company is on a $12 million growth raise to commercialize its breakthrough heart health technology, which received FDA clearance recently. Be Secure focuses on making preventive rather than reactive heart health solutions, leveraging their powerful, device-agnostic software that offers high accuracy ECG readings in consumer and medical devices alike, such as the latest versions of the Whoop and Fitbit devices. Alan elaborates on how the recent challenges faced by Philips, a significant player in heart monitoring technology, present both a testament to the need for better solutions and an opportunity for Be Secure to make a substantial impact on the market. Alan details the company's innovative use of cybersecurity experts and detailed signal processing to develop technology that bridges consumer wellness and medical-grade ECG technology. He highlights how Be Secure's cloud-based and on-device solutions offer transformative accuracy and efficiency in heart monitoring, even earning the interest of major insurers like Blue Cross Blue Shield. The conversation turns to the scalability and swift deployment of Be Secure's solutions in medical environments, emphasizing how their data quality can accelerate and improve diagnosis in cardiologists' workflows. Alan stresses the importance of their upcoming scale-up and commercial focus, particularly in filling the funding gap to expedite the deployment of their remarkable technology in the healthcare space. We also learn about Be Secure's financials and investment strategy, which involves contributions from venture capital and venture debt providers. Alan emphasizes ongoing discussions with top medical companies and the anticipated rapid revenue growth fueled by the latest FDA clearance. The episode wraps with Alan addressing some practical questions about scaling, design timelines, and the lifecycle of deals with their partners, giving a comprehensive view of Be Secure's promising future. For more updates and opportunities to engage with Alan and Be Secure, stay tuned to Investor Connect.    Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at:   Check out our other podcasts here:   For Investors check out:   For Startups check out:   For eGuides check out:   For upcoming Events, check out    For Feedback please contact info@tencapital.group    Please , share, and leave a review. Music courtesy of .

Scientific researchers in Rhode Island are reeling from canceled grants and other potential cuts to federal funding for their work. Globe Rhode Island's Steph Machado just finished a story for Rhode Island PBS Weekly about the effects of these cuts. She joins host Ed Fitzpatrick to talk about what she learned. Tips and ideas? Email us at rinews@globe.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Clay is an American inventor and serial entrepreneur who holds more than 250 patents worldwide and is the Founder and Chairman of Ember, a global consumer electronics and life sciences brand best known for the Ember Mug, Ember Baby Bottle, and Ember Cube, all three of which independently have been named TIME Magazine's Best Inventions of the year. Ember was also recently named one of TIME Magazine's 100 Most Influential Companies in the world. Top 3 Value Bombs 1. Founder's gut can be a very powerful thing. 2. The team is the No. 1 factor. Putting together an incredible powerhouse team is key. 3. Inch by inch life's a cinch. Buy the yard, life's hard. Take one bite at a time and keep chugging it forward. Check out Clay's patented technology temperature control mugs and other products - Ember Sponsors The Speaker Lab - Want to learn how to get booked and paid to speak. Go to EOFire.com/speaker to grab your spot for our LIVE training on May 28th, and learn how to get booked and paid to speak. ThriveTime Show - Become the next success story, schedule a free consultation and request tickets to join Football Star, Tim Tebow and President Trump's Son, Eric Trump at Clay Clark's next business conference today at - ThrivetimeShow.com/eofire.  

Channing Hamlet, Managing Director and Co-Founder of Objective, Investment Banking & Valuation, joins Amanda Ma, CEO & Founder of Innovate Marketing Group, to discuss the rising "flight to quality" in the event industry. Learn how consolidation is transforming the landscape — and how event businesses can adapt, scale, and thrive in a shifting market.About the guest:Channing Hamlet is the Managing Director and Co-Founder of Objective, Investment Banking & Valuation. He leads the firm's Business Services & Life Sciences Practice. With over 25 years of experience in investment banking and business valuation, Channing brings deep expertise and strategic insight to Objective's clients. His recent notable transactions include the sale of 360 Destination Management to H.I.G. Capital and Supreme to Trinity Hunt Partners. An active member of the Los Angeles advisor community, Channing has served on the boards of the Exit Planning Institute, ACG LA, and EO LA. He is also passionate about philanthropy, particularly through his involvement with Reality Changers.  Prior to joining Objective, Mr. Hamlet served as a Managing Director of Cabrillo Advisors, where he was instrumental in both leading their M&A execution and growing the valuation practice from inception into a national entity serving more than 700 clients in five years. Previously, he served as a Director at Vistage; Principal at LLR Partners, a $260 million private-equity firm; and member of Legg Mason's Investment Banking group. He has a Master's Degree in Operations Research and a Bachelor of Science in Mechanical Engineering from Cornell University. He holds FINRA Series 7, 63 and 79 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.Connect with Channing Hamlet on LinkedIn hereRead about the sale of 360 Destination Management Group hereDownload the The Introspective CEO's Guide to Selling a Business, a high-level workbook covering key considerations for those contemplating a sale here.Objective, Investment Banking & Valuation is a leading firm serving middle market companies across key industries including Business Services, Consumer, Healthcare Tech, Life Sciences, Manufacturing, and Technology. We offer M&A advisory through our investment banking group and a full suite of valuation services for tax, financial reporting, and strategic planning. Since 2006, our team has completed over 500 M&A deals and thousands of valuations. Learn more at objectiveibv.comThis podcast episode is for informational purposes only and does not constitute investment, legal, or tax advice. Securities offered through BA Securities, LLC, Member FINRA, SIPC. Objective and BA Securities, LLC are separate, unaffiliated entities.EventUp is brought to you by Innovate Marketing Group. An award-winning Corporate Event and Experiential Marketing Agency based in Los Angeles, California. Creating Nationwide Immersive Event Experiences to help brands connect with people. To learn more, click here⁠⁠.Follow us!Find us on ⁠⁠LinkedIn, ⁠⁠⁠⁠EventUp Podcast LinkedIn⁠⁠ , and ⁠⁠Instagram

Solving the “Undruggable” Disease Problem with Goldilocks MoleculesIn this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer's, certain cancers, and rare genetic disorders.Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces.We also talk about the Goldilocks Zone of drug design, how Third Law's chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right.

Today's guest is Brice Challamel, Head of AI products and Innovation at Moderna. With experience working across five continents, he brings a global perspective to driving AI adoption, innovation management, and measurable results in life sciences. Brice joins Emerj Managing Editor Matthew DeMello to explore how Moderna is embedding AI into both its tools and corporate culture to scale collaboration, accelerate product development, and improve regulatory outcomes. He breaks down how AI is augmenting human creativity, enhancing team decision-making, and supporting patient engagement efforts, while keeping human insight at the center of AI strategy. Brice also shares lessons from other industries to shed light on what's ahead for AI in regulated sectors like life sciences, where the technology has the potential to improve operational efficiency, vaccine adoption, and broader public health outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast! This episode is sponsored by MSTRO. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

In this episode, host Sandy Vance sits down with Dr. Will Morris, Chief Medical Officer at Ambience Healthcare, to explore how AI is transforming the healthcare industry. From enhancing clinical documentation to improving patient care and supporting back-office operations, Ambience is creating intelligent solutions tailored for the entire healthcare ecosystem.Dr. Morris shares insights on how AI, when used as an assistive—not replacement—tool, can help alleviate clinician burnout and empower medical professionals to focus on what matters most: delivering compassionate, human-centered care. Whether you're a healthcare leader, clinician, or innovator, this episode offers practical insights into leveraging AI to drive real value across your organization.In this episode, they talk about:● AI should assist—not replace—medical professionals, enabling them to focus on essential human-centered care.● AI is not a commodity; it must address critical pain points to drive real value.● Ambient AI must work for all specialties, not just primary care. AI models must be tuned to the nuances of each specialty.● Reducing burnout is just the start. When coding-aware, Ambient AI greatly improves clinical documentation integrity and provides coding support at the point-of-care, capturing other lost revenue.● Always measure results, outputs, and processes when implementing new healthcare technologies.● The effectiveness of any system depends on the quality and consistency of clinical documentation.● Successful AI adoption requires a unified, enterprise-wide strategy.A Little About Will:Will Morris, MD, MBA, is board-certified in Internal Medicine and is a health technology leader, currently serving as Chief Medical Officer at Ambience Healthcare. In this role, he drives the company's vision for clinical AI, collaborating with leading health systems to transform clinician workflows and improve patient care. Before joining Ambience, Dr. Morris was Chief Medical Information Officer at Google Cloud Healthcare and Life Sciences, contributing to cutting-edge healthcare innovations. He previously held leadership roles at Cleveland Clinic, including Chief Innovation Officer and Associate Chief Information Officer, overseeing clinical IT systems and health IT advancements.

In this episode, Stephanie Major, a senior at Iowa State University, outlines a research project that aimed to better understand how bacon becomes discolored under varying types of retail lights. With Major as co-leader of the research team, the study involved treating cured bacon with natural antioxidants and then packaging the product in aerobic (overwrap) and anaerobic (vacuum packed) containers. Major and Dr. Terry Hauser, associate director at Iowa State's College of Agriculture and Life Sciences, explain the results of the study, which found that the type of packaging was more effective than an antioxidant treatment alone in preventing photo-oxidation in bacon in storage or on retail shelves.

Comment on this episode by going to KDramaChat.comToday, we'll be discussing Episode 9 of When Life Gives You Tangerines, the hit K Drama on Netflix starring IU as Oh Ae-sun, Park Bo-gum as Yang Gwan-sik as young adults, and Moon So-ri as Oh Ae-sun and Park Hae-joon as Yang Gwan-sik as older adults. We discuss:The song featured during the recap: "Midnight Walk" by IU, a sweet ballad of longing that reflects Geum Myeong's and Ae Sun's emotional states of mind.How this episode subtly shifts focus to Geum Myeong as the central figure, possibly revealing the show as her coming-of-age story.The Baeksang Awards wins in 2025, including Best Drama, Best Supporting Actress, Best Supporting Actor, and Best Screenplay for When Life Gives You Tangerines!Our shoutouts to Lori and Seven Seas, who shared their love for the podcast and personal stories that echo themes in the show.The Yang family's move to a cramped apartment, and Ae-sun's determination to bring her cherished mother-of-pearl armoire to their new apartment.Eun Myeong's emotional journey—his bitterness, rebellion through hairstyles, and quiet gestures of love toward Ae Sun, like placing tennis balls under his mom's chair.Geum Myeong's return from Japan and the lack of exploration of her time abroad, which disappointed both of us.The awkward and growing connection between Geum Myeong and Park Chung Seop, who keep running into each other, and who the staff at the theater want to push closer together.The breakdown of Geum Myeong and Yeong-beom's relationship, and how Park Chung Seop might be quietly emerging as a romantic lead. Does Geum Myeong marry him in the end?The Romeo and Juliet parallel between Eun Myeong and Bu Hyeon-suk, son and daughter of two families that have been intertwined forever but are enemies!The beautiful poem “Natasha, the White Donkey and Me” by Baek Seok, read by Geum Myeong from Chung Seop's notebook.A spotlight on Lee Jun-young (Jun)—his career in K-pop and K Drama, including his rap and acting performances. We love him as Park Yeong Beom in this drama!How we're excited to watch the film "The Match" on Netflix, starring Lee Byung-hun and Yoo Ah-in. This movie is about an epic match Go between a mentor and mentee! ReferencesBloomberg Innovation Index in 2021Healthcare and Life Sciences as a Strategic Focus for South KoreaNatasha, the White Donkey and Me by Baek Seok‘Ghost' Director Lauds the Korean Sense of ResponsibilityCircle of Love by Lee Jun youngAmazing rap by Jun young of U KissKal-guksu - WikipediaJjolmyeon - Wikipedia

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of Metaphore Biotechnologies. In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor Angus Liu about her transition from marketing drugs at a Big Pharma company to advancing novel technology at a young biotech startup. Hwang discusses how her upbringing in apartheid-era South Africa—and two key lessons from her career—shaped who she is today. A longtime champion of diverse talent, she emphasizes that regardless of the broader environment or the size of an organization, it’s essential to ensure “everybody has a chance of developing in their careers and that they have a level playing field.” To learn more about the topics in this episode: 'We have not seen anything similar': Novo Nordisk pens $600M obesity pact with Flagship's Metaphore 2022's Fiercest Women in Life Sciences—Angela Hwang Done deal: Pfizer completes $43B acquisition of Seagen, doubling its oncology pipeline See omnystudio.com/listener for privacy information.

Recorded at SCBio's 2025 annual conference, hosts Heather and Matthew welcome keynote speaker John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), the world's leading advocacy group for the life sciences industry. In this inspiring episode, John shares his personal journey in biotech, including his fight to improve his children's lives after a rare disease diagnosis that inspired a major film, and offers insight into what lies ahead for the industry. Tune in to hear how his story and lifelong work are transforming lives and advancing science.

Why do most recruitment companies stall at 10 to 20 people, while others scale to 100+ across continents? In this episode, you'll hear directly from someone who's done it. STR Group is a family of specialist recruitment brands focused on STEM sectors. As co-founder, Clive Hutchings has spent over two decades growing the business to more than 120 staff across the UK, Europe, and the US—all while staying profitable, adaptable, and values-driven. In this interview, Clive breaks down what it really takes to build a multi-brand, international recruitment group, the leadership philosophy behind STR's culture, and the gritty truths behind scaling a business beyond yourself. Episode Outline and Highlights [3:05] The early days: how Clive started in recruitment and his story of practicing his pitch in front of a mirror in the office. [11:37] The operational and leadership shifts needed to grow from 10 to 100+ employees [19:19] Why many recruitment founders plateau—and how to avoid it [21:09] Discussion on the best approach to train a new recruiter. [27:33] The value of having a support network around you. [32:50] What is the formula for knowing when to make your next hire? [40:00] Impact of AI: “Sales people being more sustainable, resourcing people less so.” [41:45] Clive reveals their tech stack and how AI impacts their current operations. [45:00] The relevance of cold calling in the age of AI. [52:00] Big differences between hiring in the US and the UK. [1:02:10] Learnings on expanding globally. [1:07:00] Culture and mantra that work. Leadership That Scales One of the biggest takeaways from this conversation is the importance of evolving your role as a founder. Clive credits much of STR's growth to the fact that he didn't try to do everything himself. Instead, he and his co-founder took on complementary leadership roles, allowing each to focus on their strengths while building out a business that could scale beyond them. If you're stuck juggling billing, management, and strategy, this is your sign to rethink your leadership structure. Building a scalable firm means building scalable leadership, and that starts with letting go of being the bottleneck. He also elaborated on the following: 1. Multifaceted Leadership Structure 2. Team Composition and Talent Strategy 3. High Energy and Personal Drive 4. Resilience Through Early-Stage Challenges 5. Realistic Growth Mindset Clive's success as a leader came from building a balanced team, maintaining high personal energy, fostering a resilient and realistic culture, and adapting roles and structures to match the stage of the business. Decision Factors When to Make Your Next Hire With Clive's success in scaling his team globally, I wanted to pick his brains on his thought process when deciding to make a new hire. As a recruitment business owner, this is a critical decision to make, as doing it too slowly can impede your business's growth, while doing it too rapidly can lead to longer-term problems that cost more to fix. Clive shared the following decision factors: Strategic Forecasting & Business Planning - Hiring plans are based on quarterly forecasts developed by each brand's leadership. Critical Mass & Team Size Considerations - A certain headcount is needed to reach operational momentum, but hiring must be sustainable. Smaller teams (e.g.,

Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!

Rackspace Technology leverages decades of experience and a cloud-first approach to help healthcare organizations optimize costs, drive transformation, and enhance security. In this episode, PV SubbaRao, Senior Vice President of Global Healthcare and Life Sciences at Rackspace Technology, shares how his organization partners with key healthcare sectors to drive innovation. He discusses Rackspace's evolution from early internet hosting to leading cloud solutions that optimize costs and enhance efficiency. PV highlights how the company supports EHR implementations, data center transformations, and security improvements, helping health systems achieve 18-25% savings. He also explores the future of healthcare technology, emphasizing AI, quantum computing, and extended reality as key drivers of personalized medicine and data-driven value. Join us and learn how Rackspace's specialized healthcare team can help your organization transform and scale for the future! Resources: Connect with and follow PV SubbaRao on LinkedIn. Learn more about Rackspace Technology on their LinkedIn and website.

三腳貓很榮幸邀請到擁有5000+粉絲的臉書粉專「實驗鼠的七分鐘廢文」的實驗鼠來跟大家分享自己從博士班開始在粉專分享生活和實驗室裡的大小事（鬼故事）的契機，想更認識實驗鼠「阿鼠姊姊」嗎？想知道粉專名稱是怎麼來的嗎？想聽更多粉專裡面沒有講到的鬼故事嗎？那就絕對不要錯過這一集！ 工作人員 內容製作：實驗鼠的七分鐘廢文、若晴、Angel 剪輯：若晴 後製：若晴 文案：若晴 封面：雯薇 上架：若晴 宣傳：Angel、雯薇 -- Hosting provided by SoundOn